Megan Hollasch

Shivani Gopalsami, RN, MSN, ANP-BC, AOCNP; and Tia Wheatley, DNP, RN, AOCNS, BMTCN, highlight the value of multidisciplinary approaches in hematopoietic stem cell transplantation care.

Yelena Shames, MSA, ACNP-BC, CNRN, argues that frequent hematologic evaluations may not always be warranted with immune checkpoint inhibitors.

Applying weighted blankets for 20 minutes reduced patient anxiety during cancer infusions.

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, discusses how her institution improved double-check compliance with high-alert medications.

Jessica MacIntyre, DNP, MBA, APRN, NP-C, AOCNP, describes how nurses used an app imbedded in the electronic medical record to refer patients to the Leukemia & Lymphoma Society.

Elizabeth Loach, MSN, APRN, CNS, AGCNS-BC, OCN, highlights how the Oncology Nurse Leader Council at her institution led to frontline nurse task-force engagement.

Donna Catamero, ANP-BC, OCN, CCRC, highlights best nursing practices with teclistamab.

Hilda Haynes-Lewis, PhD, ANP-BC, AOCNP, and Rosaleen Bloom, PhD, APRN, ACNS-BC, AOCNS, discuss the financial stressors that face patients undergoing radiation.

Using established guidelines to monitor and intervene early for diarrhea and neutropenia may result in longer treatment durations and sustained benefit from sacituzumab govitecan.

Patient-reported outcomes demonstrated a manageable safety profile with abemaciclib.

Extending anastrozole treatment to 10 years in postmenopausal women with hormone receptor–positive breast cancer who have no evidence of disease after 5 years of standard-of-care treatments.

Single-agent adagrasib demonstrated a manageable safety profile and meaningful clinical activity in patients with KRAS G12C–mutated solid tumors.

Findings from a real-world, retrospective analysis support the use of apalutamide for the prostate-specific antigen reduction among patients with metastatic castration-sensitive prostate cancer.

Data presented during the ONS Annual Congress offers guidance for nurses caring for patients receiving darolutamide, docetaxel, and androgen deprivation therapy.

Rita Deimler, MSN, ANP-BC, outlines best cardiac event monitoring and management practices for patients receiving the CDK4/6 inhibitor ribociclib.

An analysis of the cilta-cel safety profile yielded promising results, according to nurse investigators.

Monitoring patients for cytokine release syndrome is a key aspect of caring for patients receiving teclistamab.

Beth Faiman, PhD, MSN, APRN-BC, AOCN, discusses the growing need for advanced practitioner provider education and her role with the NP/PA center of excellence.

Nivolumab/ipilimumab may offer superior overall survival to those with non–small cell lung cancer and solid tumor histology vs acinar histology.

Isabel Octaviano, RN, details her role and experiences supporting patients during clinical trials.

To evaluate the prevalence of financial toxicity and observe the effect of Coverage and Cost-of-Care Links, a program providing financial navigation, investigators initiated a nonrandomized study.

A retrospective cohort demonstrated that patients who are treated with antibiotics within 1 year before immune checkpoint inhibitor therapy may experience worse overall survival.

Lindsay Diamond, MSN, AGNP-C, AOCNP, unpacks the significance of recent advances in the bladder cancer space.

Courtney R. Arn, APRN-CNP, discusses the recent approval of dostarlimab for patients with mismatch repair–deficient recurrent or advanced endometrial cancer.

Nurse researchers sought to improve the communication between the hematopoietic stem cell transplantation care team and pediatric patient caregivers.

Kathleen Lutz, RN, NP-BC WH, weighs in on the recent approval of mirvetuximab soravtansine-gynx for patients with folate receptor alpha (Frα)-positive, platinum-resistant ovarian cancer.

During the 2023 Tandem Meeting, Trista Carelock RN, BSN, ONC, BMT-CN, highlighted how her institution leveraged remote patient monitoring to offer outpatient CAR T-cell therapy to patients.

Data from a retrospective analysis confirm the benefit of palbociclib plus an aromatase inhibitor in elderly patients with hormone receptor–positive, HER2-negative advanced/metastatic breast cancer.

Leslie Smith, DNP, RN, APRN-CNS, BMTCN, AOCNS, highlights the pirtobrutinib approval for mantle cell lymphoma, and what she anticipates will encompass best nursing practices with the newly approved agent.

Circulating tumor DNA can be an effective biomarker that allows for assessments of early response.